Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III, randomized, double-blinded, multi-center, study to assess the efficacy of docetaxel (Taxotere) in combination with ZD6474 (Zactima) versus docetaxel (Taxotere) with placebo in subjects with locally advanced or metastatic NSCLC after failure of 1st line anti-cancer therapy

Next Previous
X
Search
Trial Profile

A phase III, randomized, double-blinded, multi-center, study to assess the efficacy of docetaxel (Taxotere) in combination with ZD6474 (Zactima) versus docetaxel (Taxotere) with placebo in subjects with locally advanced or metastatic NSCLC after failure of 1st line anti-cancer therapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vandetanib (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ZODIAC
  • Sponsors AstraZeneca; Sanofi Genzyme

    • Most Recent Events

    • 17 Nov 2015 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 09 Jul 2010 Status changed from active, no longer recruiting to completed.
    • 01 Jul 2010 Staus change from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top